Patent 9284272 was granted and assigned to AbbVie Inc. on March, 2016 by the United States Patent and Trademark Office.
Described herein are compounds, pharmaceutical compositions and methods for treating cancer, inflammation, or autoimmune disease in a subject, or for inhibiting histone methyltransferase G9a.